Key Findings:  This article will review the current knowledge of the therapeutic potential of cannabinoid receptor as a target in Alzheimer's disease and other less well-known diseases that include, among others, multiple sclerosis, bone metabolism, and Fragile X syndrome. The therapeutic applications will be addressed through the study of cannabinoid agonists acting as single drugs and multi-target drugs highlighting the CB2 receptor agonist.
Type of Study:  Meta-analysis
Study Result:  Positive
Research Location(s):  Spain
Year of Pub:  2018
Cannabinoids Studied:  Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Monoacylglycerol Lipase (MAGL)
Phytocannabinoid Source:  Not Applicable
Receptors Studied:  CB1, CB2
Citation:  Páez JA and Campillo NE. Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer's Disease and Less Well-Known Diseases. Curr Med Chem. 2019; 26:3300-3340. doi: 10.2174/0929867325666180226095132
Authors:  Páez JA, Campillo NE